Report

  1. Home
  2. Market Research Future

Meningococcal Vaccines market research report - Forecast till 2030

Market Report I 2022-11-01 I 120 Pages I Market Research Future

Meningococcal Vaccines market research report - Forecast till 2030


Market Overview
Meningococcal Vaccines Market size is anticipated to register a healthy CAGR of 7.29% during the review period to reach USD 5.91 billion by the end of 2030. The key factors that drive the worldwide meningococcal antibodies market are the Rising mindfulness and flood in movement immunizations and the expansion in Research and development for antibody innovation. Expanding Consideration in Public Vaccination Projects is supposed to help the development of the meningococcal antibodies market. In any case, the rigid administrative rules and item reviews are expected to hamper market development.
The rising mindfulness about meningococcal antibodies and expanding antimicrobial of a few Neisseria meningitides clonal buildings is prompting a flood in vaccination programs across the globe. For example, a few Neisseria meningitides clonal buildings, especially CC4821 and CC11, keep on showing protection from anti-microbials. Furthermore, expanding episodes of meningococcal infections, likewise, drive the market. Besides, a rising number of voyagers and the incorporation of meningococcal immunization as an obligatory prerequisite for a couple of nations are likewise driving the market.
Market Segmentation
The market segmentation of meningococcal immunizations market is as follows
By Vaccine Type
- Conjugate
- Subcapsular
- Polysaccharide
By Serotype
- MenACWY
- MenB/BC
- MenC
- MenAC
- MenA
By End-user
- Hospitals
- Research & Academic Institutes
- Others
Regional Analysis
North America ruled the worldwide meningococcal immunizations market in 2021. This is because of the presence of central members, a deeply grounded medical services foundation, ideal government drives for immunization improvement and conveyance, and an expansion in the quantity of Research and development associations. Moreover, adolescents, teens, and youthful grown-ups represent 21% of all meningococcal sickness cases in the US and are probably going to emphatically affect the meningococcal immunization market.
The meningococcal antibody market in Europe is being driven by non-benefit associations that give funding to explore projects, medical services proficient preparation, patient data and backing, and request driven by a critical expansion in routine vaccination.
As indicated by the European Place for Illness Counteraction and Control, obtrusive meningococcal sickness (IMD) is the main source of meningitis and septicemia, with an expected 200,000 cases happening every year. The sickness frequently advances quickly with a 8-15% case-casualty proportion. Certain European nations that are planning for a meningococcal immunization program are supporting the meningococcal immunization market.
The Asia-Pacific locale is supposed to show the most elevated CAGR from 2021 to 2030. This is because of the expanded transmission of meningococcal microbes which has brought about a critical expansion in the quantity of clinical projects for the viable improvement of meningococcal immunizations because of capricious events across various age gatherings and nations in the district. This has reinforced the Asia-Pacific meningococcal immunizations market.
Major Players
The prominent players operating in the global meningococcal vaccines market include Pfizer Inc (US), Novartis AG (Switzerland), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Sanofi S.A.(France), and Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Ltd (China), Bio-Manguinhos (Brazil).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING AWARENESS AND SURGE IN TRAVEL VACCINE

4.2.2 INCREASE IN R&D FOR VACCINE TECHNOLOGY

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY GUIDELINES AND PRODUCT RECALLS

4.4 OPPORTUNITIES

4.4.1 INCREASING INCLUSION IN NATIONAL IMMUNIZATION PROGRAMS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 BARGAINING POWER OF BUYERS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL MENINGOCOCCAL VACCINES MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON PRODUCTION OF MENINGOCOCCAL VACCINE

5.3.4 IMPACT ON KEY PLAYERS

6 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE

6.1 OVERVIEW

6.2 CONJUGATE

6.3 SUBCAPSULAR

6.4 POLYSACCHARIDE

7 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE

7.1 OVERVIEW

7.2 MENACWY

7.3 MENB/BC

7.4 MENC

7.5 MENAC

7.6 MENA

8 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 RESEARCH & ACADEMIC INSTITUTES

8.4 OTHERS

9 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 JAPAN

9.4.2 CHINA

9.4.3 INDIA

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA-PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL

10.6.2 PARTERSHIP/AGREEMENT

10.7 FINANCIAL MATRIX

10.7.1 SALES (USD MILLION), 2021

10.7.2 R&D EXPENDITURE (USD MILLION), 2021

11 COMPANY PROFILES

11.1 PFIZER INC.

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS/SERVICES OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 NOVARTIS AG

11.2.1 COMPANY OVERVIEWS

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS/SERVICES OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 SANOFI S.A.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS/SERVICES OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 SERUM INSTITUTE OF INDIA PVT. LTD.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS/SERVICES OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 GLAXOSMITHKLINE PLC.

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS/SERVICES OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 MERCK & CO., INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 KEY STRATEGIES

11.7 INCEPTA PHARMACEUTICALS LTD.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS/SERVICES OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 BIO-MED

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 WALVAX BIOTECHNOLOGY CO., LTD.

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS/SERVICES OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 BIO-MANGUINHOS

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS/SERVICES OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 4 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR CONJUGATE, BY REGION, 2018-2030 (USD MILLION)

TABLE 5 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR SUBCAPSULAR, BY REGION, 2018-2030 (USD MILLION)

TABLE 6 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR POLYSACCHARIDE, BY REGION, 2018-2030 (USD MILLION)

TABLE 7 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 8 GLOBAL: MENINGOCOCCAL VACCINES MARKET FOR MENACWY, BY REGION, 2018-2030 (USD MILLION)

TABLE 9 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENB/BC, BY REGION, 2018-2030 (USD MILLION)

TABLE 10 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENC, BY REGION, 2018-2030 (USD MILLION)

TABLE 11 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENAC, BY REGION, 2018-2030 (USD MILLION)

TABLE 12 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR MENA, BY REGION, 2018-2030 (USD MILLION)

TABLE 13 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 14 GLOBAL: MENINGOCOCCAL VACCINES MARKET FOR HOSPITALS, BY REGION, 2018-2030 (USD MILLION)

TABLE 15 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)

TABLE 16 GLOBAL: MENINGOCOCCAL VACCINES MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)

TABLE 17 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018-2030 (USD MILLION)

TABLE 18 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 19 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 20 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 21 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 22 US: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 23 US: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 24 US: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 25 CANADA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 26 CANADA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 27 CANADA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 28 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 29 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 30 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 31 EUROPE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 32 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 33 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 34 GERMANY: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 35 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 36 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 37 FRANCE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 38 UK: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 39 UK: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 40 UK: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 41 ITALY: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 42 ITALY: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 43 ITALY: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 44 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 45 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 46 SPAIN: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 47 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 48 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 49 REST OF EUROPE: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 54 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 55 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 56 JAPAN: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 57 CHINA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 58 CHINA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 59 CHINA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 60 INDIA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 61 INDIA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 62 INDIA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 63 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 64 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 65 AUSTRALIA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 66 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 67 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 68 SOUTH KOREA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 69 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 70 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 72 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018-2030 (USD MILLION)

TABLE 73 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 74 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 75 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 76 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 77 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 78 MIDDLE EAST: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 79 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 80 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 81 AFRICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 82 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018-2030 (USD MILLION)

TABLE 83 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018-2030 (USD MILLION)

TABLE 84 LATIN AMERICA: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 85 MAJOR PLAYERS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

TABLE 86 MOST ACTIVE PLAYER IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

TABLE 87 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 88 PARTERSHIP/AGREEMENT

TABLE 89 PFIZER INC: PRODUCTS/SERVICES OFFERED

TABLE 90 PFIZER INC.: KEY DEVELOPMENTS

TABLE 91 NOVARTIS AG: PRODUCTS/SERVICES OFFERED

TABLE 92 SANOFI S.A.: PRODUCTS/SERVICES OFFERED

TABLE 93 SANOFI S.A.: KEY DEVELOPMENTS

TABLE 94 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS/SERVICES OFFERED

TABLE 95 GLAXOSMITHKLINE PLC.: PRODUCTS/SERVICES OFFERED

TABLE 96 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED

TABLE 97 MERCK & CO., INC.: KEY DEVELOPMENTS

TABLE 98 INCEPTA PHARMACEUTICALS LTD.: PRODUCTS/SERVICES OFFERED

TABLE 99 BIO-MED: PRODUCTS/SERVICES OFFERED

TABLE 100 WALVAX BIOTECHNOLOGY CO., LTD.: PRODUCTS/SERVICES OFFERED

TABLE 101 BIO-MANGUINHOS.: PRODUCTS/SERVICES OFFERED

TABLE 102 BIO-MANGUINHOS.: KEY DEVELOPMENTS

?

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL MENINGOCOCCAL VACCINES MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MENINGOCOCCAL VACCINE MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL MENINGOCOCCAL VACCINE MARKET

FIGURE 9 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2021 & 2030 (USD MILLION)

FIGURE 10 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY SEROYYPE, 2021 & 2030 (USD MILLION)

FIGURE 11 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY END USER, 2021 & 2030 (USD MILLION)

FIGURE 12 GLOBAL: MENINGOCOCCAL VACCINES MARKET, BY REGION 2020 & 2030 (USD MILLION)

FIGURE 13 GLOBAL: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY REGION, 2021

FIGURE 14 NORTH AMERICA: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021

FIGURE 15 EUROPE: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021

FIGURE 16 ASIA-PACIFIC: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY COUNTRY 2021

FIGURE 17 REST OF THE WORLD: MENINGOCOCCAL VACCINES MARKET SHARE (%), BY REGION 2021

FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET

FIGURE 20 GLOBAL MENINGOCOCCAL VACCINES MARKET: COMPETITIVE LANDSCAPE

FIGURE 21 SALES 2021

FIGURE 22 R&D EXPENDITURE, 2021

FIGURE 23 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 PFIZER INC: SWOT ANALYSIS

FIGURE 25 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 NOVARTIS AG: SWOT ANALYSIS

FIGURE 27 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 SANOFI S.A.: SWOT ANALYSIS

FIGURE 29 SERUM INSTITUTE OF INDIA PVT. LTD.: SWOT ANALYSIS

FIGURE 30 GLAXOSMITHKLINE PLC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS

FIGURE 32 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE

Related Reports

Military Data Links Market Research Report: By Platform (Ground, Airborne, Naval, Unmanned Systems, and Weapons), by Application (Command and Control, Intelligence, Surveillance, & Reconnaissance, and Radio Communications), by Component (Terminals, Radio Sets, Modems, Routers, Controllers, Transceivers, Monitors, and Others), by Band (Ka/K Band, X-Band (Air to Ground), Ku Band, S-Band, C-Band, L-Band, HF Band, VHF Band, and UHF Band), by Frequency (High Frequency, and Ultra-High Frequency), by Link Type (Link 11, Link 16, Link 22, JREAP-A, JREAP-C, and VMF), by Point-of-Sale (OEM, and Aftermarket), by Military Standard (MIL STD 6011, MIL STD 6016, MIL STD 6017, MIL STD 6020, and MIL STD 3011), and By Region (North America, Europe, Asia-Pacific, Middle East and Africa, South & Central America) Market Forecast Till 2032
 Market Report I 2025-04-21 I 307 Pages
Africa Palm Oil Market Research Report Information by Type (Crude Palm Oil, RBD Palm Oil, Palm Kernel Oil and Fractionated Palm Oil), by Application (Edible Oil, Bio-Diesel, Lubricants, Cosmetics and Others) Forecast to 2032
 Market Report I 2025-04-21 I 103 Pages
Asia-Pacific Cancer Biomarker Testing Market Research Report by Type (Product and Services), by Testing Type (Single Gene Testing and Multiple Gene Testing), by Region (China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan) Forecast to 2032
 Market Report I 2025-04-21 I 146 Pages

Don't forget we can help save time with your search, contact us and we'll prepare and send options

U.S. Automotive LED Lighting Market Research Report by Vehicle Type (Passenger Cars, Light Commercial Vehicles (LCVs) and Heavy Commercial Vehicles (HCVs)) by Adaptive Lighting (Front Adaptive Lighting, Rear Adaptive Lighting, and Ambient Adaptive Lighting) Forecast to 2032
 Market Report I 2025-04-21 I 152 Pages
UAE Tyres Market Research Report Information by Season Type (Summer and All Season), Type, Rim Size (Less Than 15 Inches, 15 to 20 Inches, and More than 20 Inches), Application (On the road and Off the road), Vehicle Type Radial and Bias), Vehicle Propulsion (ICE and Electric), and Sales Channel (Online and Offline/Retail) Forecast to 2032
 Market Report I 2025-04-21 I 150 Pages